As indicated in this study, the clinical performance of the CUE model in discriminating between malignant and nonmalignant body fluids is superior to conventional tumor markers such as CEA, NSE, and CYFRA21-1 (AUC: 0.928 vs. 0.649, 0.708, and 0.746 in the test set). This evidence concerns the gene ENO2 and neoplasm.